| Literature DB >> 33907430 |
Ayşegül Çopur Çiçek1, Ayşe Ertürk2, Nebahat Ejder1, Erva Rakici1, Uğur Kostakoğlu2, İlknur Esen Yıldız2, Songül Özyurt3, Emine Sönmez2.
Abstract
INTRODUCTION: Researching carbapenem-resistant isolates enables the identification of carbapenemase-producing bacteria and prevents their spread.Entities:
Keywords: PFGE; Pseudomonas aeruginosa; antibiotic resistance genes; epidemiology
Year: 2021 PMID: 33907430 PMCID: PMC8068481 DOI: 10.2147/IDR.S299742
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Primers Used in the Amplification of Selected Genes
| Primer | 5′-3′ Sequence | Amplicon Size (bp) | Tm (°C) | Reference |
|---|---|---|---|---|
| F- ATTTCCCGATGCAAAGCGT | 542 | 55 | [ | |
| R- TTATTCCGGAAGTCCCTGT | ||||
| F- ATGAATGTCATCACAAAAT | 927 | 50 | [ | |
| R- TCAATCCGGACTCACT | ||||
| F:CATGGTTTGGTGGTTCTTGT | 488 | 56 | [ | |
| R:ATAATTTGGCGGACTTTGGC | ||||
| F:ATTGGTCTATTTGACCGCGTC | 780 | 58 | [ | |
| R:TGCTACTCAACGACTGAGCG | ||||
| F:TGGAATTGCCCAATATTATGC | 813 | 54 | [ | |
| R:TCAGCGCAGCTTGTCGGCCATGC | ||||
| F: CGTTCTTGTCTCTCATGGCC | 796 | 52 | [ | |
| R: CCTCGCTGTGCTTGTCATCC | ||||
| F:CAGTCAAGTTCAACCCAACCG | 438 | 55 | [ | |
| R:GCGTGGTTAAGGATGAACAC | ||||
| F: TAATGCTTTGATCGGCCTTG | 353 | 52 | [ | |
| R:TGGATTGCACTTCATCTTGG | ||||
| F:GATCGGATTGGAGAACCAGA | 501 | 52 | [ | |
| R:ATTTCTGACCGCATTTCCAT |
Abbreviations: Tm, melting temperature; bp, base pairs.
Distribution of Cases According to Service and Intensive Care Units
| Total (n=70) | HAI (n=27) | CAI (n=43) | |
|---|---|---|---|
| IMICU | 14 (20.0) | 11 (40.7) | 3 (7.0) |
| SICU | 12 (17.2) | 8 (29.6) | 4 (9.3) |
| ARICU | 4 (5.7) | 3 (11.1) | 1 (2.3) |
| CVSICU | 3 (4.3) | 1 (3.7) | 2 (4.7) |
| CICU | 2 (2.8) | 1 (3.7) | 1 (2.3) |
| Other services | 35 (50.0) | 3 (11.1) | 32 (74.4) |
Abbreviations: IMUCU, Internal Medicine Intensive Care Unit; SICU, Surgery Intensive Care Unit; ARICU, Anesthesia and Reanimation Intensive Care Unit; CVSICU, Cardiovascular Surgery Intensive Care Unit; CICU, Coronary Intensive Care Unit.
Comparison of Demographic and Pathological Characteristics of HAI (n=27) and CAI (n=43) Groups
| Total | HAI | CAI | Statistics | ||
|---|---|---|---|---|---|
| n=70 | n=27 | n=43 | z, χ2 | p value | |
| 66 (17–92) | 73 (18–92) | 64 (17–89) | −1.829 | 0.067 | |
| 16 (81±6.9) | 20 (75±6.6) | (%95 confidal) | 0.0013 | ||
| 19.5 (1–72) | 22 (14–72) | 18 (1–39) | −2.921 | 0.003 | |
| Women | 27 (38.6) | 9 (33.3) | 18 (41.9) | 0.509 | 0.476 |
| Male | 43 (61.4) | 18 (66.7) | 25 (58.1) | ||
| Surgery history (last 1 month) | 15 (21.4) | 9 (33.3) | 6 (14.0) | 3.700 | 0.054 |
| Hospital history (last 3 months) | 47 (67.1) | 16 (59.3) | 31 (72.1) | 1.238 | 0.266 |
| Antibiotic utilization (last 3 months) | 53 (75.7) | 22 (81.5) | 31 (72.1) | 0.795 | 0.373 |
| – | – | ||||
| Respiratory pathologies | 19 (27.1) | 10 (37.0) | 9 (20.9) | ||
| Urinary pathologies | 13 (18.6) | 0 | 13 (30.2) | ||
| Neurological pathologies | 9 (12.9) | 5 (18.5) | 4 (9.3) | ||
| GIS pathologies | 8 (11.4) | 5 (18.5) | 3 (7.0) | ||
| CVS pathologies | 6 (8.6) | 2 (7.4) | 4 (9.3) | ||
| Trauma | 6 (8.6) | 3 (11.1) | 3 (7.0) | ||
| Soft-tissue pathologies | 5 (7.1) | 0 | 5 (11.6) | ||
| Oncological pathologies | 4 (5.7) | 2 (7.4) | 2 (4.7) | ||
| Respiratory Failure | 14 (20.0) | 6 (22.2) | 8 (18.6) | 0.136 | 0.713 |
| Mental changes | 4 (5.7) | 4 (14.8) | 0 | 6.756* | 0.019 |
| Hemodynamic instability | 4 (5.7) | 1 (3.7) | 3 (7.0) | 0.330* | 0.498 |
| Post CPR | 7 (10.0) | 4 (14.8) | 3 (7.0) | 1.132* | 0.253 |
Note: *Fisher’s exact test.
Diagnosis, Clinical Features and Risk Factors of HAI (n =27) and CAI (n =43) Groups
| Total | HAI | CAI | Statistics | ||
|---|---|---|---|---|---|
| n=70 | n=27 | n=43 | z, | p value | |
| VAP (ventilator-associated pneumonia) | 13 (18.6) | 13 (48.2) | 0 | - | - |
| KSI (blood stream infection) | 6 (8.6) | 6 (22.2) | 0 | ||
| HP (hospital pneumonia) | 6 (8.6) | 6 (22.2) | 0 | ||
| HUTI (hospital urinary tract infection) | 1 (1.4) | 1 (3.7) | 0 | ||
| UTI (urinary tract infection) | 16 (22.9) | 0 | 16 (37.2) | ||
| CAP (community-associated pneumatic) | 16 (22.9) | 0 | 16 (37.2) | ||
| STI (soft tissue infection) | 6 (8.5) | 0 | 6 (14.0) | ||
| IAI (intra-abdominal infection) | 3 (4.2) | 0 | 3 (6.9) | ||
| CBSI (community-bloodstream infection) | 2 (2.9) | 0 | 2 (4.7) | ||
| Meningitis | 1 (1.4) | 1 (3.7) | 0 | ||
| CVS diseases | 27 (38.6) | 12 (44.4) | 15 (34.9) | 0.640 | 0.424 |
| KOAH | 12 (17.1) | 5 (18.5) | 7 (16.3) | 0.059* | 0.526 |
| Neurological diseases | 9 (12.9) | 5 (18.5) | 4 (9.3) | 1.257* | 0.292 |
| Diabetes mellitus | 9 (12.9) | 3 (11.1) | 6 (14.0) | 0.120* | 0.517 |
| Malignant diseases | 7 (10.0) | 3 (11.1) | 4 (9.3) | 0.060* | 0.554 |
| Renal diseases | 6 (8.6) | 1 (3.7) | 5 (11.6) | 1.329* | 0.394 |
| Skin-soft tissue pathologies | 5 (7.1) | 2 (7.4) | 3 (7.0) | 0.005* | 0.645 |
| Hemodialysis | 24 (34.3) | 19 (70.4) | 5 (11.6) | 25.402 | 0.000 |
| Endotracheal application | 27 (38.6) | 23 (85.2) | 4 (9.3) | 40.307 | 0.000 |
| Enteral nutrition | 49 (70.0) | 16 (59.3) | 33 (76.7) | 2.415 | 0.120 |
| Peripheral venous catheter | 48 (68.6) | 18 (66.7) | 30 (69.8) | 0.074 | 0.786 |
| Nasogastric | 26 (37.1) | 16 (59.3) | 10 (23.3) | 9.209 | 0.002 |
| Peripheral artery catheter | 24 (34.3) | 19 (70.4) | 5 (11.6) | 25.402 | 0.000 |
| Decubitus | 22 (31.4) | 17 (63.0) | 5 (11.6) | 20.281 | 0.000 |
| Central venous catheter | 21 (30.0) | 11 (40.7) | 10 (23.3) | 2.415 | 0.120 |
| Urinary catheter | 26 (37.1) | 16 (59.3) | 10 (23.3) | 9.209 | 0.002 |
| Mechanical ventilator | 21 (30.0) | 17 (63.0) | 4 (9.3) | 22.742 | 0.000 |
| Total parenteral nutrition | 14 (20.0) | 3 (11.1) | 11 (25.6) | 2.171 | 0.141 |
| Transfusion | 14 (20.0) | 6 (22.2) | 8 (18.6) | 0.136 | 0.713 |
| Cystostomy | 13 (18.6) | 6 (22.2) | 7 (16.3) | 0.387 | 0.534 |
| Bronchoscopy | 7 (10.0) | 7 (16.3) | 0 | 4.884* | 0.038 |
| Steroid | 7 (10.0) | 3 (11.1) | 4 (9.3) | 0.060* | 0.554 |
| Tracheotomy | 3 (4.3) | 1 (3.7) | 2 (4.7) | 0.036* | 0.671 |
| Chest tube | 3 (4.3) | 0 | 3 (7.0) | 1.968* | 0.279 |
Note: *Fisher’s exact test.
Resistance Rates of P. aeruginosa Isolates
| Antibiotics | Resistant | Sensitive | Medium Sensitive |
|---|---|---|---|
| Ceftazidim | 30 (42.9) | 34 (48.6) | 6 (8.6) |
| Cefepim | 34 (48.6) | 29 (41,4) | 7 (10.0) |
| Cefoperazone | 12 (17.1) | 58 (82.9) | 0 |
| Cefoperazone-sulbactam | 10 (14.3) | 60 (85.7) | 0 |
| Piperacillin | 36 (51.4) | 30 (42.9) | 4 (5.7) |
| Piperacillin-tazobactam | 34 (48.6) | 29 (41.4) | 7 (10.0) |
| Amikacin | 10 (14.4) | 54 (77.0) | 6 (8.6) |
| Gentamicin | 12 (17.1) | 54 (77.0) | 4 (5.7) |
| Ciprofloxacin | 18 (25.7) | 47 (67.2) | 5 (7.1) |
| Levofloxacin | 28 (40.0) | 38 (54.3) | 4 (5.7) |
| Colistin | 0 | 70 (100) | 0 |
| Imipenem | 13 (18.6) | 56 (80.0) | 1 (1.4) |
| Meropenem | 18 (25.7) | 49 (70.0) | 3 (4.3) |
| Carbapenem resistance | 24 (34.3) | 46 (65.7) | 0 |
β-Lactamase Genes Identified in P. aeruginosa Isolates
| Genes | Isolate Numbers | Positive Number (%) |
|---|---|---|
| 3, 6, 16, 23*, 26, 28, 30, 33, 37, 38*, 46, 48, 50*, 53*, 56, 60, 61*, 65* | 18 (25.71) | |
| 3, 8, 4, 6, 7*, 13, 20*, 28, 29, 36*, 37, 55*, 56, 61*, 64*, 65*, 66*, 67* | 18 (25.71) | |
| 3, 4, 6, 16, 28, 36*, 37, 38*, 43, 50*, 56, 66* | 12 (17.14) | |
| 6, 7*, 9, 10, 11, 26, 27*, 28, 29, 30, 36*, 37, 38*, 43, 46, 53*, 56, 68 | 18 (25.71) | |
| 7*, 23*, 30, 33, 36* | 5 (7.14) | |
| 26 | 1 (1.42) | |
| 60 | 1 (1.42) | |
| 6, 7*, 9, 20*, 26, 28, 37, 38*, 46, 59, 60, 67* | 12 (17.14) |
Note: *Indicates community-associated samples.
Figure 1PFGE analysis of P. aeruginosa isolates generated seven major clusters (profile 1 (A1, A2, B, C, D, E), F1a, F1b, F1c, F2, G1 and G2). Community-associated samples were shown as underlined.
Epidemic Characteristics of 6 Patients in Which Other Microorganisms Were Isolated in Addition to P. aeruginosa
| Sample No | 65 | 66 | 67 | 68 | 69 | 70 |
|---|---|---|---|---|---|---|
| Sample | CSF | TAC | Blood | Blood | TAC | Urine |
| Age | 42 | 82 | 84 | 88 | 87 | 47 |
| Gender | Man | Man | Man | Women | Man | Man |
| Holding dates | 30.07.2016 | 15.05.2016 | 08.04.2016 | 06.09.2016 | 11.07.2016 | 22.06.2016 |
| 22.12.2016 | 16.08.2016 | 24.04.2016 | 06.11.2016 | 01.11.2016 | 24.08.2016 | |
| Holding time (day) | 145 | 93 | 16 | 61 | 113 | 62 |
| Service | ARICU - IMICU | IMICU | IMICU | IMICU | IMICU | IDS |
| Comorbidity or additional disease | IVTA – TSH | CRI | PTC | PTC | KOAH | NBS |
| Positive simultaneous breeding: another example | Blood -TAC | Blood | TAC | Blood - Urine | TAC | Urine |
| Positive simultaneous growth: other microorganism. | ||||||
| History of using antibiotics in the last 3 months | NO | YES | YES | YES | YES | YES |
| The fate of the patient | EX | EX | EX | EX | EX | Following |